The Gut Connection: A Narrative Review on the In-depth Analysis of Gut Microbiota and Metabolites in Depression.

IF 1.3 Q4 PHARMACOLOGY & PHARMACY
Ayesha Sultana, Md Sadique Hussain, Mudasir Maqbool, Mohit Agrawal, Ajay Singh Bisht, Navneet Khurrana, Gurvinder Singh, Rajesh Kumar
{"title":"The Gut Connection: A Narrative Review on the In-depth Analysis of Gut Microbiota and Metabolites in Depression.","authors":"Ayesha Sultana, Md Sadique Hussain, Mudasir Maqbool, Mohit Agrawal, Ajay Singh Bisht, Navneet Khurrana, Gurvinder Singh, Rajesh Kumar","doi":"10.2174/0127724328332998250118182255","DOIUrl":null,"url":null,"abstract":"<p><p>Depression is a prevalent mood disorder with significant public health implications. Despite extensive research, its precise causes remain inadequately understood. Recently, interest has surged in the role of the gut microbiome and its metabolites in the pathophysiology of depression. This review aims to provide a comprehensive overview of the relationship between gut microbiota, its metabolites, and depression while exploring potential mechanisms influencing the efficacy of antidepressant medications. A narrative review methodology was employed, synthesizing recent studies utilizing a multi-omics approach. We examined alterations in gut microbiome composition and metabolite production in individuals diagnosed with depression, discussing the technical tools and methods commonly applied in this research area. The findings indicate that individuals with depression show significant alterations in gut microbiome composition, notably an imbalance in Firmicutes, Bacteroidetes, and Actinobacteria. Changes in metabolite production, including short-chain fatty acids, tryptophan, and bile acids, were also observed. Moreover, the review highlights that antidepressant medications may exert their therapeutic effects by modulating gut microbiota and its metabolites. This review emphasizes the intricate interplay between gut microbiota, its metabolites, and depression, revealing critical insights into the mechanisms underlying antidepressant efficacy. We recommend that future research focus on elucidating these interactions to develop innovative therapeutic strategies, potentially transforming the management of depression through microbiota-targeted approaches.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Reviews in Clinical and Experimental Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0127724328332998250118182255","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Depression is a prevalent mood disorder with significant public health implications. Despite extensive research, its precise causes remain inadequately understood. Recently, interest has surged in the role of the gut microbiome and its metabolites in the pathophysiology of depression. This review aims to provide a comprehensive overview of the relationship between gut microbiota, its metabolites, and depression while exploring potential mechanisms influencing the efficacy of antidepressant medications. A narrative review methodology was employed, synthesizing recent studies utilizing a multi-omics approach. We examined alterations in gut microbiome composition and metabolite production in individuals diagnosed with depression, discussing the technical tools and methods commonly applied in this research area. The findings indicate that individuals with depression show significant alterations in gut microbiome composition, notably an imbalance in Firmicutes, Bacteroidetes, and Actinobacteria. Changes in metabolite production, including short-chain fatty acids, tryptophan, and bile acids, were also observed. Moreover, the review highlights that antidepressant medications may exert their therapeutic effects by modulating gut microbiota and its metabolites. This review emphasizes the intricate interplay between gut microbiota, its metabolites, and depression, revealing critical insights into the mechanisms underlying antidepressant efficacy. We recommend that future research focus on elucidating these interactions to develop innovative therapeutic strategies, potentially transforming the management of depression through microbiota-targeted approaches.

肠道联系:抑郁症患者肠道微生物群和代谢物深度分析的叙述性综述。
抑郁症是一种普遍存在的情绪障碍,具有重大的公共卫生影响。尽管进行了广泛的研究,但其确切原因仍未得到充分的了解。最近,肠道微生物群及其代谢物在抑郁症病理生理中的作用引起了人们的兴趣。本文旨在全面概述肠道微生物群及其代谢物与抑郁症之间的关系,同时探索影响抗抑郁药物疗效的潜在机制。采用叙事回顾方法,综合利用多组学方法的最新研究。我们研究了被诊断为抑郁症的个体肠道微生物组成和代谢物产生的变化,讨论了该研究领域常用的技术工具和方法。研究结果表明,抑郁症患者的肠道微生物组成发生了显著变化,尤其是厚壁菌门、拟杆菌门和放线菌门的失衡。代谢产物的变化,包括短链脂肪酸、色氨酸和胆汁酸,也被观察到。此外,该综述强调抗抑郁药物可能通过调节肠道微生物群及其代谢物来发挥其治疗作用。这篇综述强调了肠道微生物群及其代谢物与抑郁症之间复杂的相互作用,揭示了抗抑郁药疗效机制的关键见解。我们建议未来的研究重点是阐明这些相互作用,以开发创新的治疗策略,通过针对微生物群的方法潜在地改变抑郁症的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
9.10%
发文量
55
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信